激肽释放酶-激肽系统：治疗创伤性脑损伤希望靶点.docVIP

激肽释放酶-激肽系统：治疗创伤性脑损伤的希望靶点 创伤性脑损伤是外力导致的脑组织损伤，严重者可威胁生命，因此它是一个世界范围内的重要公共健康问题。在美国，每年约有170万创伤性脑损伤患者，约43％的病人接受住院治疗，因为创伤性脑损伤会发展为长期身体残疾和一些心理疾病，如神经认知缺陷、癫痫症和抑郁症。原发性脑创伤是不可逆的，并通常无法治愈。在继发性损伤过程中，包括血脑屏障紊乱和炎症，会导致创伤性脑损伤加重。除了急性脑创伤，近年来越发明确的是一些创伤性脑损伤会发展成进行性脑萎缩和痴呆，这被称为“慢性创伤性脑损伤”。据推测，在这些“慢性创伤性脑损伤”条件下，神经炎症起着决定性的作用。创伤性脑损伤的治疗方案是有限的，因为目前为止还没有过的FDA批准的创伤性脑损伤治药物疗。 德国维尔茨堡大学医院Christiane Albert-Weissenberger教授认为，考虑到与创伤性脑损伤高度相关的社会经济负担，新的临床治疗选择已经迫在眉睫。因为创伤性脑损伤的病理生理情况涉及继发性脑损伤的多种机制，成功的治疗策略必须针对其主要病理特征。根据目前的科学证据，以激肽释放酶--激肽系统为靶点的药物治疗成为改善创伤性脑损伤的希望。相关内容发表在2015年6月第6期《中国神经再生研究（英文版）》杂志上。 Article: The kallikrein-kinin system: a promising therapeutic target for traumatic brain injury by Sarah Hopp, Christiane Albert-Weissenberger, (Department of Neurology, University Hospital Würzburg, Würzburg, Germany) Hopp S, Albert-Weissenberger C (2015) The kallikrein-kinin system: a promising therapeutic target for traumatic brain injury. Neural Regen Res 10(6):885-886. 欲获更多资讯：/ The kallikrein-kinin system: a promising therapeutic target for traumatic brain injury Traumatic brain injury (TBI), which results from an outside force causing mechanical disruption of brain tissue, is potentially life-threatening and therefore a critical public health problem throughout the world. In the USA, approximately 1.7 million individuals per year sustain a TBI, and about 43% of patients hospitalized because of TBI develop long-term physical disability as well as psychological disorders, such as neurocognitive deficits, epilepsy, and depression. The primary brain damage that occurs due to the mechanical disruption of brain tissue is usually irreversible and therapeutically inaccessible. In the sequel, secondary injury processes, including blood–brain barrier disturbances and inflammation, contribute to the exacerbation of traumatic brain damage. One major predictor of outcome is the development of cerebral edema in the acute phase after brain injury. In addition to acute TBI, it has become evident over recent years that some TBI patients d